BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial,randomized, sham-controlled trial |
| |
| Affiliation: | 1. School of Psychiatry, University of New South Wales/Black Dog Institute, Sydney, NSW, Australia;2. Sheppard Pratt Health System, Clinical Research Programs, Baltimore, MD, USA;3. Department of Biomedical Engineering, City College of New York, New York, NY, USA;4. Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA;5. Department of Psychiatry and Behavioural Sciences, Duke University School of Medicine, Durham, NC, USA;6. Division of Translational Research, and Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD, USA;7. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA;8. Rowan University School of Osteopathic Medicine, Cherry Hill, NJ, USA;1. INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Psychiatric Disorders: From Resistance to Response ΨR2 Team, Centre Hospitalier Le Vinatier, F-69678, France;2. University Claude Bernard Lyon 1, Villeurbanne F-69000, France;3. AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris, Cedex 10, France;4. Fondation FondaMental, Créteil 94000, France;5. Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, Laboratory of Neurosciences (LIM-27), University of São Paulo, São Paulo, Brazil;6. University of Toronto, Centre for Addiction and Mental Health, Canada;7. Inserm, U1144, Paris F-75006, France;8. Université Paris Diderot, Sorbonne Paris Cité, UMR-S 1144, Paris F-75013, France;9. CHU Lyon, Hôpital Edouard Herriot, Department of Psychiatry Emergencies, France;10. Lyon Neuroscience Research Center, Psychiatric Disorders: From Resistance to Response ΨR2 Team, Centre Hospitalier Le Vinatier, F-69678, France |
| |
| Abstract: | ![]()
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation intervention that modifies cortical excitability according to the stimulation parameters. Preclinical and clinical studies in healthy volunteers suggest that tDCS induces neuroplastic alterations of cortical excitability, which might explain its clinical effects in major depressive disorder (MDD). We therefore examined whether tDCS, as compared to the antidepressant sertraline, increases plasma brain-derived neurotrophic factor (BDNF) levels, a neurotrophin associated with neuroplasticity. Patients (n=73) with major depressive disorder were randomized to active/sham tDCS and sertraline/placebo (four groups) in this 6-week, double-blind, placebo-controlled trial. We measured BDNF plasma levels at baseline and endpoint, observing no significant changes of BDNF levels after treatment. In addition, no significant changes were observed in responders and non-responders as well as no relationships between BDNF levels and clinical and psychopathological variables related to depression. Thus, in one of the few placebo-controlled trials evaluating BDNF changes over an antidepressant treatment course, we did not observe BDNF increase regardless of clinical improvement in depressed patients. Regarding tDCS, BDNF plasma levels might not be a good candidate biomarker to evaluate depression improvement or be a predictor of response in patients treated with tDCS, as our results showed that BDNF increase was not necessary to induce clinical response. Finally, our findings do not support a relationship between BDNF and improvement of depression. |
| |
| Keywords: | Brain-derived neurotrophic factor Transcranial direct current stimulation Major depressive disorder Sertraline Non-invasive brain stimulation Neuroplasticity |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
